We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Henry Schein (HSIC): Beats Q3 Earnings, Revenue in Line
Read MoreHide Full Article
Headquartered in Melville, NY, Henry Schein Inc. (HSIC - Free Report) is a global leading provider of healthcare products and services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein serves more than 1 million customers and has operations in 28 countries. The company entered the prestigious Standard & Poor's (S&P) 500 Index in Mar, 2015.
Currently, Henry Schein has a Zacks Rank #4 (Sell) but that could change following its impressive third quarter 2016 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings:The Zacks Consensus Estimate remained steady at $1.65 per share over the last 60 days. Henry Schein’s adjusted earnings per share of $1.68 beat this estimate by 1.8%.
Revenues: Henry Schein posted revenues of $2.865 billion, almost in line with the Zacks Consensus Estimate for revenues of $2.872 billion.
Key Stats: Revenues derived from Henry Schein’s Dental segment grew 5.1% year over year to $1.3 billion, while Animal Health segment recorded sales of $790.2 million, up 7.9% compared with the prior-year quarter. Revenues from Medical segment increased 7.1% year over year to $639.6 million, while sales from Technology and Value-added services segment grew 16.7% to $104.6 million.
Major Factors: Henry Schein ended third quarter of 2016 on an impressive note, with all four of its operating segments delivering strong year over year growth. Management was particularly upbeat with strategic acquisitions that the company made in its technology and Value–Added Services segment. Henry Schein’s adjusted EPS guidance for 2016 remains the same.
Stock Price: Following the earnings release, share prices did not show any significant movement in the pre-market trading session.
Check back later for our full write up on this Henry Schein earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Henry Schein (HSIC): Beats Q3 Earnings, Revenue in Line
Headquartered in Melville, NY, Henry Schein Inc. (HSIC - Free Report) is a global leading provider of healthcare products and services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein serves more than 1 million customers and has operations in 28 countries. The company entered the prestigious Standard & Poor's (S&P) 500 Index in Mar, 2015.
Currently, Henry Schein has a Zacks Rank #4 (Sell) but that could change following its impressive third quarter 2016 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings:The Zacks Consensus Estimate remained steady at $1.65 per share over the last 60 days. Henry Schein’s adjusted earnings per share of $1.68 beat this estimate by 1.8%.
HENRY SCHEIN IN Price and EPS Surprise
HENRY SCHEIN IN Price and EPS Surprise | HENRY SCHEIN IN Quote
Revenues: Henry Schein posted revenues of $2.865 billion, almost in line with the Zacks Consensus Estimate for revenues of $2.872 billion.
Key Stats: Revenues derived from Henry Schein’s Dental segment grew 5.1% year over year to $1.3 billion, while Animal Health segment recorded sales of $790.2 million, up 7.9% compared with the prior-year quarter. Revenues from Medical segment increased 7.1% year over year to $639.6 million, while sales from Technology and Value-added services segment grew 16.7% to $104.6 million.
Major Factors: Henry Schein ended third quarter of 2016 on an impressive note, with all four of its operating segments delivering strong year over year growth. Management was particularly upbeat with strategic acquisitions that the company made in its technology and Value–Added Services segment. Henry Schein’s adjusted EPS guidance for 2016 remains the same.
Stock Price: Following the earnings release, share prices did not show any significant movement in the pre-market trading session.
Check back later for our full write up on this Henry Schein earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>